Compare the market
Start at country level, where launch pricing, reimbursement, access conditions, and entry timing become comparable.
Drug intelligence for launch decisions
See the marketbefore the launch planhardens.
Drugloose is a proposed subscription intelligence platform that turns public, country-specific evidence into a clearer view of what to compare, verify, and prioritize next.
Proposed platformPublic sources onlyBuilt for market-access + BD
01The outcome
From scattered sources to one defensible view.
The job is not to add another broad intelligence platform. It is to make a time-sensitive market question easier to frame, compare, and carry into the next decision.
The first validation path stays focused: one or two therapy areas, a small set of priority markets, and the evidence a mid-size pharma team needs for launch pricing, reimbursement, access, and country prioritization.
Concept study / source trail
02The evidence standard
Evidence with its source still attached.
Drugloose is being designed to organize clinical status, public pricing and reimbursement, market-access agreements, regulatory pathways, patent timelines, and generic or biosimilar entry around the molecule and country in question.
ACountry-specific by default
BSource-cited and dated
CClear about recency and limits
03The working view
Three moves, one decision trail.
Concept study / market view
Keep the source attached
Every finding is designed to retain its public source, geography, date, and the limits of what it can support.
Prioritize the next diligence
Use the visible gaps and caveats to decide what deserves expert review before a launch recommendation hardens.
04For the first team
A sharper starting point for market-access and BD.
Built for the moment a team is asking whether a drug is worth taking deeper into a country, a therapy area, or a launch plan.
Planned views
Drug-level, country-level, and therapy-area dashboards with filtering and export.
Primary users
Mid-size pharma teams preparing launch, pricing, reimbursement, or BD decisions.
05The boundary
Transparent by design
Public price is not net price.
Published list, reimbursement, and tender evidence can orient a question. It cannot stand in for confidential rebates, negotiated discounts, or expert diligence. Drugloose should make that distinction visible, not bury it in a footnote.
See the proposed workflow06The next question